RUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the ...

This study represents first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

“I am honored to join the Company at this pivotal time as we advance our human clinical trials and create a strategic regulatory program for the Continuous Blood Glucose Monitor (CBGM),” said ...

and over 7.1 million each of Series A and Series B Warrants. Amid these financial developments, Glucotrack's Continuous Blood Glucose Monitor (CBGM) technology demonstrated high accuracy in a ...

Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose monitor (CBGM). The study included participants with both type 1 and type 2 ...

Glucotrack (Nasdaq:GCTK) today said it hit a significant milestone in the development of its continuous blood glucose monitor (CBGM). Our sister site, Drug Delivery Business News, reports today ...

These puzzles challenge the readers to find subtle differences between two identical pictures. The best thing about puzzles is that they boost concentration and memory and provide an effective ...